Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany
Restricted accessResearch articleFirst published online November 24, 2020
Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany
The National Institute of Aging and Alzheimer’s Association’s diagnostic recommendations for preclinical Alzheimer’s disease (AD) and mild cognitive impairment (MCI) define AD by pathological processes which can be detected by biomarkers. These criteria were established as part of a research framework intended for research purposes but progressively enter the clinical practice.
Objective:
We investigated the availability, frequency of use, interpretation, and therapeutic implications of biomarkers for the etiologic diagnosis and prognosis in MCI and subjective cognitive decline (SCD) in routine clinical care.
Methods:
We conducted a cross-sectional questionnaire survey among 215 expert dementia centers (hospitals and memory clinics) in Germany.
Results:
From the 98 centers (45.6% of contacted centers) included, two-thirds reported use of the cerebrospinal fluid (CSF) biomarkers Aβ42, tau, and phospho-tau in the diagnostic workup of MCI and one third in SCD. CSF biomarker analysis was more often employed by neurological (MCI 84%; SCD 42%) compared to psychiatric institutions (MCI 61%; SCD 33%; p≤0.001). Although dementia experts disagreed on the risk of progression associated with different CSF biomarker constellations, CSF biomarker results guided therapeutic decisions: ∼40% of responders reported to initiate cholinesterase inhibitor therapy in MCI and 18% in SCD (p = 0.006), given that all CSF biomarkers were in the pathological range.
Conclusion:
Considering the vast heterogeneity among dementia expert centers in use of CSF biomarker analysis, interpretation of results, and therapeutic consequences, a standardization of biomarker-based diagnosis practice in pre-dementia stages is needed.
JackCRJr., AlbertMS, KnopmanDS, McKhannGM, SperlingRA, CarrilloMC, ThiesB, PhelpsCH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 257–262.
2.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
JessenF, AmariglioRE, BuckleyRF, van der FlierWM, HanY, MolinuevoJL, RabinL, RentzDM, Rodriguez-GomezO, SaykinAJ, SikkesSAM, SmartCM, WolfsgruberS, WagnerM (2020) The characterisation of subjective cognitive decline. Lancet Neurol19, 271–278.
5.
van HartenAC, SmitsLL, TeunissenCE, VisserPJ, KoeneT, BlankensteinMA, ScheltensP, van der FlierWM (2013) Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology81, 1409–1416.
6.
WolfsgruberS, PolcherA, KopparaA, KleineidamL, FrolichL, PetersO, HullM, RutherE, WiltfangJ, MaierW, KornhuberJ, LewczukP, JessenF, WagnerM (2017) Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis58, 939–950.
7.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr., KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
8.
ColijnMA, GrossbergGT (2015) Amyloid and tau biomarkers in subjective cognitive impairment. J Alzheimers Dis47, 1–8.
9.
EckerstromM, GothlinM, RolstadS, HessenE, EckerstromC, NordlundA, JohanssonB, SvenssonJ, JonssonM, SacuiuS, WallinA (2017) Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer’s disease in a memory clinic sample. Alzheimers Dement (Amst)8, 96–107.
10.
SchwedaM, KogelA, BartelsC, WiltfangJ, SchneiderA, SchicktanzS (2018) Prediction and early detection of Alzheimer’s dementia: Professional disclosure practices and ethical attitudes. J Alzheimers Dis62, 145–155.
11.
DeuschlG, MaierW (2016) Deutsche Gesellschaft für Psychiatrie und Psychotherapie PuND, Deutsche Gesellschaft für Neurologie (DGN).
van MaurikIS, SlotRER, VerfaillieSCJ, ZwanMD, BouwmanFH, PrinsND, TeunissenCE, ScheltensP, BarkhofF, WattjesMP, MolinuevoJL, RamiL, WolfsgruberS, PetersO, JessenF, BerkhofJ, van der FlierWM, Alzheimer’s Disease Neuroimaging Initiative (2019) Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. Alzheimers Res Ther11, 33.
14.
RitchieC, SmailagicN, Noel-StorrAH, UkoumunneO, LaddsEC, MartinS (2017) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev3, CD010803.
15.
CarandiniT, ArighiA, SacchiL, FumagalliGG, PietroboniAM, GhezziL, ColombiA, ScarioniM, FenoglioC, De RizMA, MarottaG, ScarpiniE, GalimbertiD (2019) Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: From biological biomarkers to clinical syndromes. Alzheimers Res Ther11, 84.
16.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM, HedrickS, PappasV, ThiesWH, Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce (2013) Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement9, e1–16.
17.
BlennowK, ZetterbergH (2018) Biomarkers for Alzheimer’s disease: Current status and prospects for the future. J Intern Med284, 643–663.
KuhlmannJ, AndreassonU, PanneeJ, BjerkeM, PorteliusE, LeinenbachA, BittnerT, KoreckaM, JenkinsRG, VandersticheleH, StoopsE, LewczukP, ShawLM, ZegersI, SchimmelH, ZetterbergH, BlennowK, proteinsIWGoSoC (2017) CSF Abeta1-42 - an excellent but complicated Alzheimer’s biomarker - a route to standardisation. Clin Chim Acta467, 27–33.
20.
MattssonN, AndreassonU, PerssonS, CarrilloMC, CollinsS, ChalbotS, CutlerN, Dufour-RainfrayD, FaganAM, HeegaardNH, Robin HsiungGY, HymanB, IqbalK, KaeserSA, LachnoDR, LleoA, LewczukP, MolinuevoJL, ParchiP, RegeniterA, RissmanRA, RosenmannH, SancesarioG, SchroderJ, ShawLM, TeunissenCE, TrojanowskiJQ, VandersticheleH, VandijckM, VerbeekMM, ZetterbergH, BlennowK, Alzheimer’s Association QC Program Work Group (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement9, 251–261.
21.
StewartT, ShiM, MehrotraA, AroP, SoltysD, KerrKF, ZabetianCP, PeskindER, TaylorP, ShawLM, TrojanowskiJQ, ZhangJ, and from the Alzheimer’s Disease Neuroimaging Initiative (2019) Impact of pre-analytical differences on biomarkers in the ADNI and PPMI studies: Implications in the era of classifying disease based on biomarkers. J Alzheimers Dis69, 263–276.
22.
van MaurikIS, ZwanMD, TijmsBM, BouwmanFH, TeunissenCE, ScheltensP, WattjesMP, BarkhofF, BerkhofJ, van der FlierWM, Alzheimer’s Disease Neuroimaging Initiative (2017) Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurol74, 1481–1491.
23.
van MaurikIS, VosSJ, BosI, BouwmanFH, TeunissenCE, ScheltensP, BarkhofF, FrolichL, KornhuberJ, WiltfangJ, MaierW, PetersO, RutherE, NobiliF, FrisoniGB, SpiruL, Freund-LeviY, WallinAK, HampelH, SoininenH, TsolakiM, VerheyF, KloszewskaI, MecocciP, VellasB, LovestoneS, GalluzziS, HerukkaSK, SantanaI, BaldeirasI, de MendoncaA, SilvaD, ChetelatG, EgretS, PalmqvistS, HanssonO, VisserPJ, BerkhofJ, van der FlierWM, Alzheimer’s Disease Neuroimaging Initiative (2019) Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): A modelling study. Lancet Neurol18, 1034–1044.
24.
SnitzBE, WangT, CloonanYK, JacobsenE, ChangCH, HughesTF, KambohMI, GanguliM (2018) Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimers Dement14, 734–742.
25.
RaschettiR, AlbaneseE, VanacoreN, MagginiM (2007) Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials. PLoS Med4, e338.
26.
PetersenRC, LopezO, ArmstrongMJ, GetchiusTSD, GanguliM, GlossD, GronsethGS, MarsonD, PringsheimT, DayGS, SagerM, StevensJ, Rae-GrantA (2018) Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology90, 126–135.
27.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, HedrickS, PappasV, CarrilloMC, HartleyDM, Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging (2013) Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement9, e106–109.
28.
HarkinsK, SankarP, SperlingR, GrillJD, GreenRC, JohnsonKA, HealyM, KarlawishJ (2015) Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther7, 26.
29.
BocchettaM, GalluzziS, KehoePG, AgueraE, BernabeiR, BullockR, CeccaldiM, DartiguesJF, de MendoncaA, DidicM, EriksdotterM, FelicianO, FrolichL, GertzHJ, HallikainenM, HasselbalchSG, HausnerL, HeuserI, JessenF, JonesRW, KurzA, LawlorB, LleoA, Martinez-LageP, MecocciP, MehrabianS, MonschA, NobiliF, NordbergA, RikkertMO, OrgogozoJM, PasquierF, PetersO, SalmonE, Sanchez-CastellanoC, SantanaI, SarazinM, TraykovL, TsolakiM, VisserPJ, WallinAK, WilcockG, WilkinsonD, WolfH, YenerG, ZekryD, FrisoniGB (2015) The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimers Dement11, 195–206 e191.
